755 related items for PubMed ID: 17494881
1. A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy.
Jha V, Ganguli A, Saha TK, Kohli HS, Sud K, Gupta KL, Joshi K, Sakhuja V.
J Am Soc Nephrol; 2007 Jun; 18(6):1899-904. PubMed ID: 17494881
[Abstract] [Full Text] [Related]
2. Prednisolone and azathioprine in membranous nephropathy: a 10-year follow-up study.
Goumenos DS, Ahuja M, Davlouros P, El Nahas AM, Brown CB.
Clin Nephrol; 2006 May; 65(5):317-23. PubMed ID: 16724651
[Abstract] [Full Text] [Related]
3. Long-term outcomes of idiopathic membranous nephropathy in Japanese patients treated with low-dose cyclophosphamide and prednisolone.
Eriguchi M, Oka H, Mizobuchi T, Kamimura T, Sugawara K, Harada A.
Nephrol Dial Transplant; 2009 Oct; 24(10):3082-8. PubMed ID: 19465558
[Abstract] [Full Text] [Related]
4. Efficacy of a second course of immunosuppressive therapy in patients with membranous nephropathy and persistent or relapsing disease activity.
du Buf-Vereijken PW, Wetzels JF.
Nephrol Dial Transplant; 2004 Aug; 19(8):2036-43. PubMed ID: 15187191
[Abstract] [Full Text] [Related]
5. Early versus late start of immunosuppressive therapy in idiopathic membranous nephropathy: a randomized controlled trial.
Hofstra JM, Branten AJ, Wirtz JJ, Noordzij TC, du Buf-Vereijken PW, Wetzels JF.
Nephrol Dial Transplant; 2010 Jan; 25(1):129-36. PubMed ID: 19666912
[Abstract] [Full Text] [Related]
6. Cytotoxic therapy for membranous nephropathy and renal insufficiency: improved renal survival but high relapse rate.
du Buf-Vereijken PW, Branten AJ, Wetzels JF, Membranous Nephropathy Study Group.
Nephrol Dial Transplant; 2004 May; 19(5):1142-8. PubMed ID: 14993502
[Abstract] [Full Text] [Related]
7. Effective treatment administration of cyclophosphamide in membranous nephropathy.
Dede F, Ayili D, Sahiner S.
J Nephrol; 2008 May; 21(4):560-5. PubMed ID: 18651546
[Abstract] [Full Text] [Related]
8. [Comparison of two cyclophosphamide treatment regimens in nephrotic patients with chronic glomerulonephritis].
Krasnova TN, Shilov EM, Tareeva IE, Gordovskaia NB, Lavrova ON, Miroshnichenko NG, Troepol'skaia OV, Ivanova LV, Ivanov AA.
Ter Arkh; 1998 May; 70(6):14-7. PubMed ID: 9695216
[Abstract] [Full Text] [Related]
9. Corticosteroids and ciclosporin A in idiopathic membranous nephropathy: higher remission rates of nephrotic syndrome and less adverse reactions than after traditional treatment with cytotoxic drugs.
Goumenos DS, Katopodis KP, Passadakis P, Vardaki E, Liakopoulos V, Dafnis E, Stefanidis I, Vargemezis V, Vlachojannis JG, Siamopoulos KC.
Am J Nephrol; 2007 May; 27(3):226-31. PubMed ID: 17389782
[Abstract] [Full Text] [Related]
10. Short- and long-term efficacy of oral cyclophosphamide and steroids in patients with membranous nephropathy and renal insufficiency. Study Group.
Branten AJ, Wetzels JF.
Clin Nephrol; 2001 Jul; 56(1):1-9. PubMed ID: 11499653
[Abstract] [Full Text] [Related]
11. Intravenous pulse cyclophosphamide and steroids induce immunological and clinical remission in New-incident and relapsing primary membranous nephropathy.
Kanigicherla DAK, Hamilton P, Czapla K, Brenchley PE.
Nephrology (Carlton); 2018 Jan; 23(1):60-68. PubMed ID: 27778424
[Abstract] [Full Text] [Related]
12. Immunosuppressive therapy with cyclophosphamide and prednisolone in severe idiopathic membranous nephropathy.
Kibriya MG, Tishkov I, Nikolov D.
Nephrol Dial Transplant; 1994 Jan; 9(2):138-43. PubMed ID: 8190328
[Abstract] [Full Text] [Related]
13. Idiopathic membranous nephropathy and nephrotic syndrome: outcome in the era of evidence-based therapy.
McQuarrie EP, Stirling CM, Geddes CC.
Nephrol Dial Transplant; 2012 Jan; 27(1):235-42. PubMed ID: 21558430
[Abstract] [Full Text] [Related]
14. The remission of nephrotic syndrome with cyclosporin treatment does not attenuate the progression of idiopathic membranous nephropathy.
Goumenos DS, Kalliakmani P, Tsakas S, Sotsiou F, Vlachojannis JG.
Clin Nephrol; 2004 Jan; 61(1):17-24. PubMed ID: 14964453
[Abstract] [Full Text] [Related]
15. The Medical Research Council trial of short-term high-dose alternate day prednisolone in idiopathic membranous nephropathy with nephrotic syndrome in adults. The MRC Glomerulonephritis Working Party.
Cameron JS, Healy MJ, Adu D.
Q J Med; 1990 Feb; 74(274):133-56. PubMed ID: 2189149
[Abstract] [Full Text] [Related]
16. Comparison of immunosuppressive therapeutic regimens in patients with nephrotic syndrome due to idiopathic membranous nephropathy.
Kosmadakis G, Filiopoulos V, Smirloglou D, Skarlas P, Georgoulias C, Michail S.
Ren Fail; 2010 Jun; 32(5):566-71. PubMed ID: 20486839
[Abstract] [Full Text] [Related]
17. Prognosis and management of membraneous nephropathy.
Pahari DK, Das S, Dutta BN, Banerjee D.
J Assoc Physicians India; 1993 Jun; 41(6):350-1. PubMed ID: 8005970
[Abstract] [Full Text] [Related]
18. Cyclosporin A treatment for idiopathic membranous nephropathy.
Yao X, Chen H, Wang Q, Tang Z, Hu W, Yin G, Liu Z, Li L.
Chin Med J (Engl); 2001 Dec; 114(12):1305-8. PubMed ID: 11793859
[Abstract] [Full Text] [Related]
19. Idiopathic membranous nephropathy: outline and rationale of a treatment strategy.
du Buf-Vereijken PW, Branten AJ, Wetzels JF.
Am J Kidney Dis; 2005 Dec; 46(6):1012-29. PubMed ID: 16310567
[Abstract] [Full Text] [Related]
20. Introduction of a cyclophosphamide-based treatment strategy and the risk of ESRD in patients with idiopathic membranous nephropathy: a nationwide survey in the Netherlands.
Hofstra JM, Wetzels JF.
Nephrol Dial Transplant; 2008 Nov; 23(11):3534-8. PubMed ID: 18559961
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
